|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||133.64 / 176.85|
Wall Street was torn in two with the energy sector marching the Dow Jones Industrial Average higher, while health care and tech weighed on the Nasdaq.
The Dow Jones Industrial Average leads markets on Wednesday as a rally in crude oil lights a fire under the energy sector.
The company has seen shares fall 60% since market's close Tuesday.
Sub-Analysis From Phase 3 TOWER Study Compares Health-Related Quality of Life of BLINCYTO® (Blinatumomab) to Standard of Care Chemotherapy
Jim Cramer finds reasons to like AEP, AMGN, DOW and HEI.
This rally isn't just about Trump, Cramer says. He thinks investors are cheering the economic outlook.
Investors in biotech stocks appear to be happy with a Trump win and Mizuho's senior biotech analyst says companies in the sector could continue to climb in 2017.
STRIVE Study Met its Primary Endpoint, Adding to Body of Episodic Migraine Prevention Data
Supported by Phase 3 Study in Patients With Non-Squamous Non-Small Cell Lung Cancer
Nearly Two-Thirds of Patients Experienced Plaque Regression With Repatha on Top of Optimized Statin Therapy
Scientists From Premier Educational and Research Institutions Reveal What the Future may Look Like
Investors have convinced themselves that President Donald Trump is going to make drug stocks great again. Will it last?
Romosozumab Data at the ACR/ARHP Annual Meeting Show Significant Bone Mineral Density Gains at the Lumbar Spine, Total Hip and Femoral Neck Compared to Placebo at Six and 12 Months
First Treatment Advance for Secondary Hyperparathyroidism in More Than a Decade and First Intravenous Calcimimetic to Help Healthcare Providers Lower Key Lab Values
Here are 15 stocks that boast solid dividend yields and are growing earnings.
Check out these 15 stocks that boast solid dividend yields and are growing earnings.
Initial Phase 3 Registrational Study Planned in Relapsed or Refractory Multiple Myeloma Patients
How health care investors deal with Donald Trump as the next U.S. president and Republicans maintaining control of Congress is hard to forecast because few envisioned this scenario playing out.
While Amgen has a strong pipeline, it may not be enough to replace the legacy treatments that are losing market share.
21 Abstracts to be Featured Provide Real-World and Disease State Insights, Highlight Clinical and Health Economic Impact of Rheumatologic Diseases and Osteoporosis
First and Only Systemic Drug Approved in the U.S. to Treat Children Affected by This Serious Inflammatory Disease
But we could see more volatility in the market.
Jim Cramer says there are other reasons not to buy Valeant, other than the criminal investigation.